Respiree
Clinician innovators across the region see the next phase of healthcare AI focusing on trust and responsible adoption after a year of rapid experimentation.
Predictions from Australia to Southeast Asia highlight where AI, telehealth, and platform consolidation are headed next.
Respiree is also preparing to file for regulatory approval for its AI tool in the United States and across Australia, New Zealand, and Asia.
Also, Heuron started expanding to Japan following an exclusive deal to supply its stroke imaging AI.
Also, Japan has approved iRhythm's AI-based continuous ECG monitoring system.
The wearable device directly measures respiration to predict deterioration in COPD patients.